Preoperative serum leptin levels in patients with endometrial cancer and its correlation with prognostic variables

Purpose of investigation: Since leptin is believed to be a key player in carcinogenesis, a study has been designed to investigate the relationship between leptin levels and endometrial cancer. Methods: A study including 30 patients with endometrial cancer and 30 healthy controls was carried out between November 2008 and July 2009 in Hacettepe University Hospital. All patients with endometrial cancer underwent a complete surgical staging procedure including lymphadenectomy. Preoperative leptin levels of endometrial cancer patients and healthy controls were compared. The relationships between leptin levels and stage, grade, histological type and lymph node status of endometrial cancer cases were evaluated. Results: The mean serum leptin levels were 16.9 ng/ml among endometrial cancer cases and 19.0 ng/ml among controls (p = 0.32). Of endometrial cancer cases, the mean leptin level was found to be 15.8 ng/ml for Stage I and 18.5 ng/ml for Stage II-IV disease (p = 0.34). The figure was 17.7 ng/ml for endometrioid and 13.2 ng/ml for non-endometrioid type of tumor (p = 0.24). The mean leptin levels of 16.3 ng/ml for grade 1 and 19.9 ng/ml for grade 2-3 tumors were observed (p = 0.07). The cases with positive and negative lymph nodes had leptin levels of 20.2 ng/ml and 16.1 ng/ml, respectively (p = 0.30). Conclusions: Serum leptin levels in endometrial cancer patients were similar to healthy controls. Leptin did not show any significant correlation with stage, grade, histological type and node metastases in endometrial cancer.

Leptin; Endometrial cancer; Obesity

[1] Reeves G.K., Pirie K., Green J., Spencer E., Bull D.: “Cancer incidence and mortality in relation to body mass index in the Million Women Study: cohort study”. BMJ, 2007, 335, 1134.

[2] Bernstein L.M., Kvatchevskaya J.O., Poroshina T.E., Kovalenko I.G., Tsyrlina E.V., Zimarina T.S. et al.: “Insulin resistance, its consequences for the clinical course of the disease and possibilities of correction in endometrial cancer”. J. Cancer Res. Clin. Oncol., 2004, 130, 687.

[3] Gnacinska M., Malgorzewicz S., Stojek M., Lysiak-Szydlowska W., Sworczak K.: “Role of adipokines in complications related to obesity: a review”. Adv. Med. Sci., 2009, 54, 150.

[4] Boden G.: “Obesity, free fatty acids, insulin resistance”. Curr. Opin. Endocrinol. Diab., 2001, 8, 235.

[5] Rose D.P.: “Breast cancer and obesity”. Nutr. Cancer, 2003, 45, 1.

[6] Sierra-Honimann M.R., Nath A.K., Murakami C.: “Biological action of leptin as an angiogenic factor”. Science, 1998, 281, 1683.

[7] Ratke J., Entschladen F., Nigemann B., Zänker K.S., Lang K. et al.: “Leptin stimulates the migration of colon carcinoma cells by multiple signaling pathways”. Endocr. Relat. Cancer, 2010, 17, 179.

[8] Carino C., Olawayie A.B., Cherfils S., Serikawa T., Lynch M.P., Rueda B.R., Gonzalez R.R.: “Leptin regulation of proangiogenic molecules in benign and cancerous endometrial cells”. Int. J. Cancer, 2008, 123, 2782.

[9] Gong C., Liu Y., Xia W., Yin J., Wang D.H., Sheng H.: “The role of ERK1/2 in leptin promoting the proliferation of human endometrial cancer cell line Ishikawa”. Ai Zheng, 2007, 26, 1211.

[10] Petridou E., Belechri M., Dessypris N., Koukoulomatis P., Diakomanolis E., Spanos E.: “Leptin and body mass index in relation to endometrial cancer risk”. Ann. Nutr. Metab., 2002, 46, 147.

[11] Yuan S.F., Tsai K., Chung Y., Chan T., Yeh Y., Tsai L., Su J.: “Aberrant expression and posiisble involvement of the leptin receptor in endometrial cancer”. Gynecol. Oncol., 2004, 92, 769.

[12] Cymbaluk A., Chudecka-Glaz A., Rzepka_Gorska I.: “Leptin levels in serum depending on body mass index in patients with endometrial hyperplasia and cancer”. Eur. J. Obstet. Gynecol. Reprod. Biol., 2008, 136, 74.

[13] Ashizawa N., Yahata T., Quan J., Adachi S., Yoshihara K., Tanaka K.: “Seum leptin-adiponectin ratio and endometrial cancer risk in postmenopausal female subjects”. Gynecol. Oncol., 2010, 119, 65.